Tag: HansohGSK
-
Week In Review: Two Billion-Dollar Deals As 2023 Nears End – Hansoh-GSK; Nona-Pfizer
PeopleImages Deals and Financings GSK acquired ex-Greater China rights to a second ADC from Jiangsu’s Hansoh Pharma in a $1.7 billion agreement (see story). GSK’s latest acquisition, HS-20093, is a B7-H3 targeted antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) payload that is in China Phase I/II trials for solid tumor cancers. Hansoh will receive…